The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Open accessAbstract
Diabetes is associated with a two to three-fold increase in risk of cardiovascular disease. However, intensive glucose-lowering therapy aiming at reducing HbA1c to a near-normal level failed to suppress cardiovascular events in recent randomized controlled trials. HbA1c reflects average glucose level rather than glycemic variability. In in vivo and in vitro studies, glycemic variability has been shown to be associated with greater reactive oxygen species production and vascular damage, compared to chronic hyperglycemia. These findings suggest that management of glycemic variability may reduce cardiovascular disease in patients with diabetes; however, clinical studies have shown conflicting results. This review summarizes the current knowledge on glycemic variability and oxidative stress, and discusses the clinical implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“control has been shown to reduce the development of CVD as well as diabetic microangiopathy during long-term follow up in patients with both type 1 (T1DM) and type 2 diabetes (T2DM), so-called legacy effects [3,4].”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“On the other hand, recent clinical trials aiming at reducing HbA1c to a near-normal level in patients with T2DM have failed to show an additional benefit on CVD outcomes [5–7].”
BackgroundSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“diabetes are at two to three-fold increased risk of developing cardiovascular disease (CVD), and CVD remains the major cause of death in patients with diabetes [1,2].”
BackgroundAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310 · cited 1×
“examined the effect of oscillating glucose on oxidative stress and endothelial function in healthy subjects and patients with type 2 diabetes [49].”
BackgroundThe Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Prevention and management of type 2 diabetes: dietary components and nutritional strategies
Ley, S. H., Hamdy, O., Mohan, V., & Hu, F. B. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60613-9 · Cited by 1,301
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., & Sekikawa, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.920 · Cited by 1,165
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 1×
“secretion [126,127].”
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933 · cited 1×
“The incidence of all and severe hypoglycemia was significantly higher in the intensive glucose control group, although the investigators concluded that hypoglycemia was not a cause of increased death in the intensive therapy group [67].”
BackgroundSurvival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667 · cited 1×
“although the use of prandial insulin results in a higher risk of hypoglycemia and weight gain compared with the use of basal insulin [128].”
BackgroundHanefeld, M. (2004) · European Heart Journal · doi:10.1016/s0195-668x(03)00468-8 · Cited by 641
Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group (2008) · Diabetes · doi:10.2337/db07-1618 · Cited by 555 · cited 1×
“However, the DCCT investigators recently reanalyzed the data and denied their previous conclusion [23].”
BackgroundBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Effect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Fortmann, S. P., Burda, B. U., Senger, C. A., Lin, J. S., & Whitlock, E. P. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-12-201312170-00729 · Cited by 442
Esposito, K., Giugliano, D., Nappo, F., & Marfella, R. (2004) · Circulation · doi:10.1161/01.cir.0000134501.57864.66 · Cited by 440 · cited 1×
“reported that treatment with repaglinide reduced postprandial hyperglycemia compared with the effect of glyburide, a sulfonylurea, and more patients treated with repaglinide showed regression of carotid IMT compared with those treated with glyburide [84].”
ResultThe glycation of albumin: Structural and functional impacts
Rondeau, P., & Bourdon, E. (2011) · Biochimie · doi:10.1016/j.biochi.2010.12.003 · Cited by 433 · cited 1×
“GA has not only been shown to be a marker of GV, but GA itself has also been postulated to promote atherosclerosis [56].”
BackgroundChow, E., Bernjak, A., Williams, S., Fawdry, R. A., Hibbert, S., Freeman, J., Sheridan, P. J., & Heller, S. R. (2014) · Diabetes · doi:10.2337/db13-0468 · Cited by 403 · cited 1×
“lead to a sudden death, so called “dead-in-bed” syndrome [71–75].”
BackgroundHirakawa, Y., Arima, H., Zoungas, S., Ninomiya, T., Cooper, M., Hamet, P., Mancia, G., Poulter, N., Harrap, S., Woodward, M., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0199 · Cited by 363 · cited 1×
“examined the association between visit-to-visit GV of FPG or HbA1c and vascular events in a cohort of the Action in Diabetes and Vascular Disease: the Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, which consisted of 4399 patients with a median follow-up of 3 years [43].”
BackgroundRaz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351
Cavalot, F., Pagliarino, A., Valle, M., Di Martino, L., Bonomo, K., Massucco, P., Anfossi, G., & Trovati, M. (2011) · Diabetes Care · doi:10.2337/dc10-2414 · Cited by 322 · cited 1×
“In the San Luigi Gonzaga Diabetes Study, a 14-year follow-up of 505 patients with T2DM, HbA1c and 2 h postprandial blood glucose level after lunch were significantly associated with CVD events and mortality [32].”
BackgroundClinical impact of glycated albumin as another glycemic control marker
Koga, M., & Kasayama, S. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-138 · Cited by 290 · cited 1×
“past one to two months [19].”
Selvin, E., Rawlings, A. M., Grams, M., Klein, R., Sharrett, A. R., Steffes, M., & Coresh, J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70199-2 · Cited by 262
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
The ORIGIN Trial Investigators, Mellbin, L. G., Rydén, L., Riddle, M. C., Probstfield, J., Rosenstock, J., Díaz, R., Yusuf, S., & Gerstein, H. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht332 · Cited by 247
Nathan, D. M., McGee, P., Steffes, M. W., Lachin, J. M., & the DCCT/EDIC Research Group (2014) · Diabetes · doi:10.2337/db13-0782 · Cited by 214
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Ceriello, A., Novials, A., Ortega, E., La Sala, L., Pujadas, G., Testa, R., Bonfigli, A. R., Esposito, K., & Giugliano, D. (2012) · Diabetes · doi:10.2337/db12-0224 · Cited by 155
Fukuda, M., Tanaka, A., Tahara, Y., Ikegami, H., Yamamoto, Y., Kumahara, Y., & Shima, K. (1988) · Diabetes · doi:10.2337/diab.37.1.81 · Cited by 145
Cox, D. J., Kovatchev, B. P., Julian, D. M., Gonder-Frederick, L. A., Polonsky, W. H., Schlundt, D. G., & Clarke, W. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989471 · Cited by 137 · cited 2×
“It has been reported that greater GV predicted more frequent hypoglycemic events, including severe hypoglycemia requiring assistance from a third person, in patients with T1DM [64–66].”
BackgroundMellbin, L. G., Malmberg, K., Rydén, L., Wedel, H., Vestberg, D., & Lind, M. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs384 · Cited by 57
Postprandial lipaemia and vascular disease
Kolovou, G., & Ooi, T. C. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283606971 · Cited by 32 · cited 1×
“In addition to hyperglycemia-induced oxidative stress, postprandial dyslipidemia, mainly triglyceridemia, may also contribute to vascular damage and CVD [55].”
Background
Cited by
Ito, F., Sono, Y., & Ito, T. (2019) · Antioxidants · doi:10.3390/antiox8030072 · Cited by 535
Papachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk
Chia, C. W., Egan, J. M., & Ferrucci, L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312806 · Cited by 454
Sun, B., Luo, Z., & Zhou, J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01200-7 · Cited by 168
Antioxidant Phytochemicals as Potential Therapy for Diabetic Complications
Akpoveso, O.-O. P., Ubah, E. E., & Obasanmi, G. (2023) · Antioxidants · doi:10.3390/antiox12010123 · Cited by 90
Metadata
- Authors
- Saisho, Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2014-10-13
- Volume
- 15
- Issue
- 10
- Pages
- 18381-18406
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2017456187
- Cited by
- 195
- References
- 47
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.